AbbVie to buy neuroscience drugmaker Cerevel Therapeutics for $8.7bn
US-based pharmaceutical company AbbVie has agreed to acquire Cerevel Therapeutics, a company focused on developing treatments for neuroscience diseases, for a total of $8.7bn. Cerevel has a pipeline